TW202304429A - 新型雜芳基胺基丙醇衍生物 - Google Patents

新型雜芳基胺基丙醇衍生物 Download PDF

Info

Publication number
TW202304429A
TW202304429A TW111114222A TW111114222A TW202304429A TW 202304429 A TW202304429 A TW 202304429A TW 111114222 A TW111114222 A TW 111114222A TW 111114222 A TW111114222 A TW 111114222A TW 202304429 A TW202304429 A TW 202304429A
Authority
TW
Taiwan
Prior art keywords
oxy
phenyl
amino
mmol
propan
Prior art date
Application number
TW111114222A
Other languages
English (en)
Chinese (zh)
Inventor
安德列亞斯 柯迪考斯基
玉剛 劉
瑞諾 馬丁 魯德
克利斯汀 馬可
渥甘 米茲
提爾 羅伊恩
卡斯汀 史帕卡
格哈德 索馬
謝天
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202304429A publication Critical patent/TW202304429A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111114222A 2021-04-16 2022-04-14 新型雜芳基胺基丙醇衍生物 TW202304429A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021087655 2021-04-16
WOPCT/CN2021/087655 2021-04-16
US202263311231P 2022-02-17 2022-02-17
US63/311,231 2022-02-17

Publications (1)

Publication Number Publication Date
TW202304429A true TW202304429A (zh) 2023-02-01

Family

ID=81346222

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114222A TW202304429A (zh) 2021-04-16 2022-04-14 新型雜芳基胺基丙醇衍生物

Country Status (13)

Country Link
US (2) US11932630B2 (https=)
EP (2) EP4628163A1 (https=)
JP (1) JP2024513988A (https=)
KR (1) KR20230172533A (https=)
CN (1) CN117015537A (https=)
AU (1) AU2022259056A1 (https=)
BR (1) BR112023019043A2 (https=)
CA (1) CA3210344A1 (https=)
ES (1) ES3049013T3 (https=)
MX (1) MX2023012211A (https=)
PY (1) PY2228191A (https=)
TW (1) TW202304429A (https=)
WO (1) WO2022219546A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828839B (zh) * 2019-01-11 2024-01-11 瑞士商諾華公司 使用lta4h抑制劑治療化膿性汗腺炎之方法
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
CN120365187B (zh) * 2025-04-23 2025-10-10 辽宁众辉生物科技有限公司 一种一锅法合成杀菌剂中间体肟醚的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP3493359B1 (ja) 2003-03-20 2004-02-03 宣美 辛島 イオン泳動式治療装置
ATE403654T1 (de) * 2003-07-28 2008-08-15 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
WO2010062829A1 (en) 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
EP2582666B1 (en) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
JP6080227B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するためのベンゾジオキサン
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
NZ719169A (en) * 2013-12-20 2018-08-31 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN111094242B (zh) 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3669872A4 (en) 2017-08-18 2021-05-05 Shanghai Ennovabio Pharmaceuticals Co., Ltd. FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF
EP3697758B1 (en) 2017-10-17 2022-07-06 Novartis AG Sulphonamides and compositions thereof for treating conditions associated with nlrp activity
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
EP3817815A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
CN112513026B (zh) 2018-07-31 2025-02-25 诺华股份有限公司 Lta4h抑制剂的晶型
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
US20220387397A1 (en) 2018-10-24 2022-12-08 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CR20210235A (es) 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
EP3880666B1 (en) 2018-11-13 2023-06-28 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN113015730A (zh) 2018-11-13 2021-06-22 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US20230059136A1 (en) 2018-11-16 2023-02-23 Novartis Ag The compounds and compositions for treating conditions associated with nlrp activity
CN113286784A (zh) 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
TWI828839B (zh) 2019-01-11 2024-01-11 瑞士商諾華公司 使用lta4h抑制劑治療化膿性汗腺炎之方法
EP3914583A1 (en) 2019-01-22 2021-12-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3914585A1 (en) 2019-01-23 2021-12-01 Novartis AG Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202122078A (zh) * 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Also Published As

Publication number Publication date
US20220348566A1 (en) 2022-11-03
BR112023019043A2 (pt) 2023-12-05
EP4628163A1 (en) 2025-10-08
CN117015537A (zh) 2023-11-07
AU2022259056A1 (en) 2023-08-31
US11932630B2 (en) 2024-03-19
PY2228191A (es) 2023-09-21
US20240199593A1 (en) 2024-06-20
JP2024513988A (ja) 2024-03-27
EP4323062B1 (en) 2025-07-23
EP4323062A1 (en) 2024-02-21
CA3210344A1 (en) 2022-10-20
ES3049013T3 (en) 2025-12-12
WO2022219546A1 (en) 2022-10-20
MX2023012211A (es) 2023-10-26
KR20230172533A (ko) 2023-12-22

Similar Documents

Publication Publication Date Title
TW202304429A (zh) 新型雜芳基胺基丙醇衍生物
JP6545199B2 (ja) ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
TW202328076A (zh) Sos1抑制劑及其用途
US7968571B2 (en) 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease
JP5281287B2 (ja) ヘテロ環置換ベンズイミダゾール誘導体
TW202128706A (zh) 新型雜環化合物
KR20190117006A (ko) 키나제 억제제로서의 아미노트리아졸로피리딘
TW201802085A (zh) 經雜芳基取代之吡啶及使用方法
JP5855668B2 (ja) 結核に対して有用な３−アミノ−ピラゾール誘導体
CN103998432A (zh) 双环化合物
TW202233614A (zh) 作為激酶抑制劑之三唑并吡啶化合物
JP5828188B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP2008520718A (ja) アルツハイマー病の治療のためのβ−セクレターゼ阻害剤として有用な２，３，４，６−置換ピリジル誘導体化合物
CN109311878B (zh) 作为γ-分泌酶调节剂的三唑并吡啶类化合物
KR20160124188A (ko) 오렉신 수용체 길항제로서의 치환된 시클로펜탄, 테트라히드로푸란 및 피롤리딘
AU2019387290A1 (en) Pyrazoles as modulators of hemoglobin
EA052392B1 (ru) Производные гетероариламинопропанола в качестве ингибиторов lta4h
WO2014077235A1 (ja) ２－ピリドン化合物
TW201619141A (zh) 唑羧酸衍生物
US10562882B2 (en) Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
WO2016204135A1 (ja) ５員ヘテロ環誘導体
JP6048533B2 (ja) ２−ピリドン化合物を含有する医薬
CN121752559A (zh) 吗啉促食欲素受体拮抗剂
HK40062310A (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
CN116829547A (zh) 因子XIIa抑制剂